Company Description
Bluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States.
It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components.
The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis.
In addition, it develops biomarkers for detection of other diseases such as hsTNT/I for myocardial injury and NT-proBNP for cardiac heart failure.
It has a license and supply agreement with Toray Industries, Inc. for making and distributing the protein detection chips.
Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
| Country | United States |
| IPO Date | Nov 10, 2021 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 10 |
| CEO | Indranil Dey |
Contact Details
Address: 360 Massachusetts Avenue Acton, Massachusetts United States | |
| Website | https://www.bluejaydx.com |
Stock Details
| Ticker Symbol | BJDX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001704287 |
| CUSIP Number | 095633103 |
| ISIN Number | US0956333019 |
| Employer ID | 47-3552922 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Indranil Dey | Principal Financial, Accounting & Executive Officer, President, Chief Executive Officer and Director |
| Dr. Jason Cook | Chief Technology Officer |
| Dr. Mark W. Feinberg M.D. | Chief Medical Advisor |
| Kevin Vance | Chief Commercial Officer |
| Les DeLuca | Vice President of Operations |
| Mark W. Feinberg | Chief Medical Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 04, 2024 | 8-K | Current Report |
| Nov 18, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 07, 2024 | 10-Q | Quarterly Report |
| Oct 24, 2024 | 8-K | Current Report |
| Oct 16, 2024 | DEFA14A | Filing |
| Oct 16, 2024 | 8-K | Current Report |
| Sep 10, 2024 | DEF 14A | Filing |
| Aug 30, 2024 | PRE 14A | Filing |